Interrelated aldosterone and parathyroid hormone mutually modify cardiovascular mortality risk

International Journal of Cardiology

Volumn 184, Issue 1, 2015, Pages 710-716

  Tomaschitz, Andreas ^a,b,c   Pilz, Stefan ^b,d   Rus Machan, Jutta ^a   Meinitzer, Andreas ^b   Brandenburg, Vincent M ^e   Scharnagl, Hubert ^b   Kapl, Martin ^b   Grammer, Tanja ^f   Ritz, Eberhard ^g   Horina, Jörg H ^b   Kleber, Marcus E ^f   Pieske, Burkert ^b,c   Kraigher Krainer, Elisabeth ^b,c   Hartaigh, Bríain Ó ^h,i   Toplak, Hermann ^b   Van Ballegooijen, Adriana J ^d   Amrein, Karin ^b   Fahrleitner Pammer, Astrid ^b   März, Winfried ^b,f,j  

^a Specialist Clinic for Rehabilitation Bad Au ee   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^h NEW YORK PRESBYTERIAN HOSPITAL   (United States)

ⁱ YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j SYNLAB ACADEMY   (Germany)

more..

Author keywords

Aldosterone; Cardiovascular mortality; Parathyroid hormone

Indexed keywords

25 HYDROXYVITAMIN D; ALDOSTERONE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CALCIUM; FIBROBLAST GROWTH FACTOR 23; HYDROCORTISONE; KLOTHO PROTEIN; MAGNESIUM; PARATHYROID HORMONE; PHOSPHATE; RENIN; BIOLOGICAL MARKER;

ADULT; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE TO RENIN RATIO; ANGIOCARDIOGRAPHY; ARTICLE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CROSS-SECTIONAL STUDY; FEMALE; FOLLOW UP; GERMANY; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; TERTIARY HEALTH CARE; AGED; BLOOD; CARDIOVASCULAR DISEASES; MIDDLE AGED; RISK FACTOR;

AGED; ALDOSTERONE; BIOMARKERS; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PARATHYROID HORMONE; RISK FACTORS;

EID: 84933563949     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.03.062     Document Type: Article

References (37)

1. A. Tomaschitz, S. Pilz, E. Ritz, et al., Aßociation of plasma aldosterone with cardiovascular mortality in patients with low estimated GFR: The Ludwigshafen Risk and Cardiovascular Health (LURIC) Study, Am. J. Kidney Dis. 57 (3) (2011) 403-414.
2. S. Pilz, A. Tomaschitz, C. Drechsler, et al., Parathyroid hormone level is aßociated with mortality and cardiovascular events in patients undergoing coronary angiography, Eur. Heart J. 31 (13) (2010) 1591-1598.
3. A. Tomaschitz, S. Pilz, Interplay between sodium and calcium regulatory hormones: A clinically relevant research field, Hypertension 63 (2) (2014) 212-214.
4. J.M. Brown, A. Vaidya, Interactions between adrenal-regulatory and calciumregulatory hormones in human health, Curr. Opin. Endocrinol. Diabetes Obes. 21 (3) (2014) 193-201.
5. C.M. Isales, P.Q. Barrett, M. Brines, W. Bollag, H. Rasmußen, Parathyroid hormone modulates angiotensin II-induced aldosterone secretion from the adrenal glomerulosa cell, Endocrinology 129 (1) (1991) 489-495.
6. G. Mazzocchi, F. Aragona, L.K. Malendowicz, G.G. Nußdorfer, PTH and PTH-related peptide enhance steroid secretion from human adrenocortical cells, Am. J. Physiol. Endocrinol. Metab. 280 (2) (2001) E209-E213.
7. V.S. Chhokar, Y. Sun, S.K. Bhattacharya, et al., Hyperparathyroidism and the calcium paradox of aldosteronism, Circulation 111 (7) (2005) 871-878.
8. S. Pilz, K. Kienreich, C. Drechsler, et al., Hyperparathyroidismin patients with primary aldosteronism: croß-sectional and interventional data from the GECOH study, J. Clin. Endocrinol. Metab. 97 (1) (2012) E75-E79.
9. L. Kovacs, M.I. Goth, I. Szabolcs, O. Dohan, A. Ferencz, G. Szilagyi, The effect of surgical treatment on secondary hyperaldosteronism and relative hyperinsulinemia in primary hyperparathyroidism, Eur. J. Endocrinol. 138 (5) (1998) 543-547.
10. B.R. Winkelmann, W. März, B.O. Boehm, et al., Rationale and design of the LURIC study-a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease, Pharmacogenomics 2 (1 Suppl. 1) (2001) S1-S73.
11. S. Trenkel, C. Seifarth, H. Schobel, E.G. Hahn, J. Hensen, Ratio of serumaldosterone to plasma renin concentration in eßential hypertension and primary aldosteronism, Exp. Clin. Endocrinol. Diabetes 110 (2) (2002) 80-85.
12. L. Desquilbet, F.Mariotti, Dose-response analyses using restricted cubic spline functions in public health research, Stat. Med. 29 (9) (2010) 1037-1057.
13. C. Maniero, A. Faßina, V. Guzzardo, et al., Primary hyperparathyroidism with concurrent primary aldosteronism, Hypertension 58 (3) (2011) 341-346.
14. J.M. Brown, J.S. Williams, J.M. Luther, et al., Human interventions to characterize novel relationships between the renin-angiotensin-aldosterone system and parathyroid hormone, Hypertension 63 (2) (2014) 273-280.
15. A. Tomaschitz, E. Ritz, B. Pieske, et al., Aldosterone and parathyroid hormone: A precarious couple for cardiovascular disease, Cardiovasc. Res. 94 (1) (2012) 10-19.
16. A. Tomaschitz, E. Ritz, B. Pieske, et al., Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease, Metabolism 63 (1) (2014) 20-31.
17. K. Olgaard, E. Lewin, S. Bro, H. Daugaard, M. Egfjord, V. Pleß, Enhancement of the stimulatory effect of calcium on aldosterone secretion by parathyroid hormone, Miner. Electrolyte Metab. 20 (5) (1994) 309-314.
18. P. Urena, X.F. Kong, A.B. Abou-Samra, et al., Parathyroid hormone (PTH)/PTH-related peptide receptor meßenger ribonucleic acids are widely distributed in rat tißues, Endocrinology 133 (2) (1993) 617-623.
19. H.N. Hulter, J.C.Melby, J.C. Peterson, C.R. Cooke, Chronic continuous PTH infusion results in hypertension in normal subjects, J. Clin. Hypertens. 2 (4) (1986) 360-370.
20. J. Voelkl, I. Alesutan, C.B. Leibrock, et al., Spironolactone ameliorates PIT1-dependent vascular osteoinduction in klotho-hypomorphic mice, J. Clin. Invest. 123 (2) (2013) 812-822.
21. V.M. Brandenburg, M.E. Kleber, et al., Fibroblast growth factor 23 (FGF23) and mortality: The Ludwigshafen Risk and Cardiovascular Health Study, Atherosclerosis 237 (1) (2014) 53-59.
22. A. Vaidya, B. Sun, C. Larson, J.P. Forman, J.S. Williams, Vitamin D3 therapy corrects the tißue sensitivity to angiotensin ii akin to the action of a converting enzyme inhibitor in obese hypertensives: An interventional study, J. Clin. Endocrinol. Metab. 97 (7) (2012) 2456-2465.
23. S.J. Silverberg, E.M. Lewiecki, L. Mosekilde, M. Peacock, M.R. Rubin, Presentation of asymptomatic primary hyperparathyroidism: Proceedings of the third international workshop, J. Clin. Endocrinol. Metab. 94 (2) (2009) 351-365.
24. S. Ljunghall, S. Jakobßon, C. Joborn, M. Palmer, J. Rastad, G. Akerstrom, Longitudinal studies of mild primary hyperparathyroidism, J. Bone Miner. Res. 6 (Suppl. 2) (1991) S111-S116 (discußion S121-114).
25. R. Pacifici, H.M. Perry III, W. Shieber, E. Biglieri, D.M. Droke, L.V. Avioli, Adrenal responses to subtotal parathyroidectomy for primary hyperparathyroidism, Calcif. Tißue Int. 41 (3) (1987) 119-123.
26. S. Pilz, A. Tomaschitz, V. Stepan, et al., Graz Endocrine Causes of Hypertension (GECOH) study: A diagnostic accuracy study of aldosterone to active renin ratio in screening for primary aldosteronism, BMC Endocr. Disord. 9 (2009) 11.
27. E. Fischer, A. Hannemann, R. Rettig, et al., A high aldosterone to renin ratio is aßociated with high serumparathyroid hormone concentrations in the general population, J. Clin. Endocrinol. Metab. 99 (3) (2014) 965-971.
28. A. Tomaschitz, S. Pilz, Aldosterone to renin ratio-a reliable screening tool for primary aldosteronism? Horm. Metab. Res. 42 (6) (2010) 382-391.
29. A.L. Runyan, V.S. Chhokar, Y. Sun, S.K. Bhattacharya, J.W. Runyan, K.T. Weber, Bone loß in rats with aldosteronism, Am. J. Med. Sci. 330 (1) (2005) 1-7.
30. V.S. Chhokar, Y. Sun, S.K. Bhattacharya, et al., Loß of bone minerals and strength in rats with aldosteronism, Am. J. Physiol. Heart Circ. Physiol. 287 (5) (2004) H2023-H2026.
31. P.H. Law, Y. Sun, S.K. Bhattacharya, V.S. Chhokar, K.T.Weber, Diuretics and bone loß in rats with aldosteronism, J. Am. Coll. Cardiol. 46 (1) (2005) 142-146.
32. F. Edelmann, A. Tomaschitz, R. Wachter, et al., Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction, Eur. Heart J. 33 (2012) 203-212.
33. A. Tomaschitz, S. Pilz, E. Ritz, A.Meinitzer, B.O. Boehm, W. März, Plasma aldosterone levels are aßociated with increased cardiovascular mortality: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study, Eur. Heart J. 31 (10) (2010) 1237-1247.
34. A. Piovesan, N. Molineri, F. Casaßo, et al., Left ventricular hypertrophy in primary hyperparathyroidism. Effects of succeßful parathyroidectomy, Clin. Endocrinol. (Oxf) 50 (3) (1999) 321-328.
35. M. Haßan, W. Qureshi, L.S. Sroujieh, et al., Interplay of parathyroid hormone and aldosterone antagonist in prevention of heart failure hospitalizations in chronic kidney disease, J. Renin-Angiotensin-Aldosterone Syst. 15 (2014) 278-285.
36. A. Tomaschitz, A. Fahrleitner-Pammer, B. Pieske, et al., Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: A randomized, double-blind, placebo-controlled trial, BMC Endocr. Disord. 12 (2012) 19.
37. J. Fuentes, P.M. Guerreiro, T. Modesto, J. Rotllant, A.V. Canario, D.M. Power, A PTH/PTHrP receptor antagonist blocks the hypercalcemic response to estradiol-17beta, Am. J. Physiol. Regul. Integr. Comp. Physiol. 293 (2) (2007) R956-R960.